Skin immunization by microneedle patch overcomes statin-induced suppression of flu vaccine response in mice

December 21, 2017 by Nadia Lelutiu, Emory University

Statin therapy is prescribed for 20 percent of the US population over the age of 40 and nearly 50 percent of the population over 75 years old to reduce the risk of cardiovascular disease by lowering blood cholesterol levels. Although statins have become a common treatment for elderly individuals at risk of coronary disease, the impact of statin use on immune responses to vaccines has been given little attention.

Recent studies have found that in , statin therapy is associated with a reduced response to influenza vaccination. Higher rates of influenza-related respiratory illness have also been reported in vaccinated statin-users compared to vaccinated non-users. This information is concerning because the aged population is already at high risk for morbidity and mortality caused by influenza, due in part to immunosenescence, or diminishing effectiveness of the immune system over time. Thus, finding a way to overcome statin-induced suppression of immune response to vaccination in older individuals is an important goal.

A new study published in Scientific Reports and led by Elena Vassilieva, Ph.D., and Richard Compans, Ph.D., at Emory University School of Medicine used a mouse model to investigate the effect of on immune responses to . They observed that long-term in aged mice reduced the immune response when influenza vaccine was administered using a standard hypodermic needle. However, the response was enhanced up to 20-fold if vaccine was administered through the skin using dissolving microneedles, a technology developed by Mark Prausnitz, Ph.D., and colleagues at Georgia Tech.

The skin immunization induces a stronger compared to the traditional injection with a needle. The microneedles are made of a dissolving polymer incorporating the vaccine, delivering it to the body through skin cells, rather than being injected into the muscle. Earlier this year, a successful human Phase I clinical trial was conducted in which the seasonal influenza vaccine was administered using microneedle patches. The present study indicates that the microneedle patch technology can be useful as an approach to counteract statin-induced immune suppression in the aging population.

Explore further: Microneedle patches for flu vaccination prove successful in first human clinical trial

More information: Elena V. Vassilieva et al. Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine, Scientific Reports (2017). DOI: 10.1038/s41598-017-18140-0

Related Stories

Microneedle patches for flu vaccination prove successful in first human clinical trial

June 27, 2017
Despite the potentially severe consequences of illness and even death, only about 40 percent of adults in the United States receive flu shots each year; however, researchers believe a new self-administered, painless vaccine ...

Studies raise questions about impact of statins on flu vaccination in seniors

October 29, 2015
A new pair of studies suggests that statins, drugs widely used to reduce cholesterol, may have a detrimental effect on the immune response to influenza vaccine and the vaccine's effectiveness at preventing serious illness ...

Microneedle vaccine patch boosts flu protection through robust skin cell immune response

March 6, 2012
Recent research found that microneedle vaccine patches are more effective at delivering protection against influenza virus in mice than subcutaneous or intramuscular inoculation. A new, detailed analysis of the early immune ...

Why statin users should still get the flu shot, even if cholesterol drugs make it less effective

February 18, 2016
Every year in the United States, about 226,000 people are hospitalized because of the flu, and 23,000 die. And about 80-90 percent of flu-related deaths occur in people over 65 years old.

Study shows H1N1 microneedle vaccine protects better than injection

July 12, 2011
(Medical Xpress) -- A vaccine delivered to the skin using a microneedle patch gives better protection against the H1N1 influenza virus than a vaccine delivered through subcutaneous or intramuscular injection, researchers ...

Recommended for you

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

How the immune system's key organ regenerates itself

January 15, 2018
With advances in cancer immunotherapy splashing across headlines, the immune system's powerful cancer assassins—T cells—have become dinner-table conversation. But hiding in plain sight behind that "T" is the organ from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.